The latest price target for LifeMD (NASDAQ:LFMD) was reported by Mizuho on March 16, 2026. The analyst firm set a price target for $8.00 expecting LFMD to rise to within 12 months (a possible 125.35% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for LifeMD (NASDAQ:LFMD) was provided by Mizuho, and LifeMD upgraded their outperform rating.

The last upgrade for LifeMD Inc happened on March 16, 2026 when Mizuho raised their price target to $8. Mizuho previously had a neutral for LifeMD Inc.

There is no last downgrade for LifeMD.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LifeMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LifeMD was filed on March 16, 2026 so you should expect the next rating to be made available sometime around March 16, 2027.

While ratings are subjective and will change, the latest LifeMD (LFMD) rating was a upgraded with a price target of $6.00 to $8.00. The current price LifeMD (LFMD) is trading at is $3.55, which is out of the analyst’s predicted range.